Navigation Links
ESMO 2012 Congress: Program preview

The final program of the ESMO 2012 Congress including all late-breaking abstract titles is online!

The ESMO 2012 Congress looks to be one of the best in this year's oncology scenario, possibly a "practice-changing" congress: results from long awaited trials; new drug approvals or new indications for drugs already used in other settings; randomized phase III studies and trials in earlier phases of research, which indicate new signals of activity or bring new concepts for future research; also studies that seem disappointing if you simply look at numbers, but with beautiful scientific rationale, for which expert and lively discussions are expected on how to move on with research agenda priorities or in the practice arena upon non-validation of the original hypothesis

Watch out for thrilling results in the following areas and make sure you don't miss the expert discussions on the future of treatments for these diseases:

  • Lung cancer: crizotinib, a new ready-to-use targeted drug for a molecularly defined sub-set of patients based on the results of the first phase III study in such setting; study results offering for the first time directions on how to treat patients with a certain EGFR mutation; first-time positive results for sorafenib treatment based on biomarker analysis in heavily pre-treated patients
  • Renal cell carcinoma: new drug in the jungle of available treatments for RCC; different strategies to target the disease
  • Melanoma: combination of MEK and BRAF inhibitors proves clinically meaningful to delay resistance
  • Early and metastatic breast cancer: answers on standard duration of adjuvant treatment for HER2-positive early breast cancer; what's behind low breast conserving surgery in the context of clinical trials;
  • Gastrointestinal tumors: what could be the role of targeted treatments for esophageal cancer progressing after chemo; combination of therapies for gastric cancer in a specific ethnicity; new targets and results of clinical studies with targeted agents in hepatocellular carcinoma
  • CNS tumors: new predictive marker identified for anti-angiogenic treatment
  • Ovarian cancer: drug combination opportunity for platinum-resistant recurrent ovarian cancer
  • Sarcoma: awaited results of a long-term academic study evaluating classical chemotherapy agents in a fashion of single versus combination first-line treatment for advanced soft tissue sarcoma

    Just to mention a few

    Not to be missed are also presentations and discussions on:

  • The economic direct and indirect burden of cancer in Europe
  • Health economics and drug cost in austerity
  • Patient awareness and understanding of personalized medicine
  • General public and oncology professional poor knowledge of risk factors for cancer
  • The need for prophylaxis of thrombosis in cancer patients
  • Future models of independent clinical research
  • Accessibility of cancer pain killers
  • Hereditary cancers and screening protocols Read the interview with Dr Judith Balmana, Chair of the ESMO 2012 Familial cancer track]

    ESMO 2012 Press timetable

    These and other interesting topics will be presented during special sessions for the media. The full text of the abstracts will be published on Monday, September 17 at 9:00 (CEST). Late-breaking abstracts and abstracts included in the press program will remain embargoed until their presentation at the Congress session or at the Press briefing, whichever comes first.

    Wednesday, 26 September, 10:00-11:00, Presseclub Concordia
    German Press Conference: Congress program highlights with specific reference to topics for the Austrian media. Featuring a.o. the Austrian Minister of Health

    Friday, 28 September, 11:30-12:30, ESMO Press Conference Room, ACV
    Opening press conference: ESMO's President welcome; Congress program highlights; Appointments for journalists; The economic direct and indirect burden of cancer in Europe

    Saturday, 29 September, 8:15-9:00, ESMO Press Conference Room, ACV
    Press briefing Day 1: Melanoma; Lung cancer; Gastrointestinal tumors

    Saturday, 29 September, 11:00-12:00 (TBC), ESMO Press Conference Room, ACV
    Press conference: What personalized medicine practically means for patients

    Sunday, 30 September, 8:15-9:00, ESMO Press Conference Room, ACV
    Press briefing Day 2: Breast cancer; Lung cancer; Promising new weapons in the fight against cancer

    Sunday, 30 September, 12:00-13:00, ESMO Press Conference Room, ACV
    Press Conference: Prevention and screening What people know about it

    Monday, 1 October, 8:15-9:00, ESMO Press Conference Room, ACV
    Press briefing Day 3: Breast cancer; Renal cell carcinoma; Gastrointestinal tumors

    Tuesday, 2 October, 9:30-10:30, ESMO Press Conference Room, ACV
    Closing press conference: Congress highlights; Top practice changes to make after ESMO 2012; Cancer care in austerity times: how to improve equal access to quality cancer care across Europe


  • Contact: Vanessa Pavinato
    European Society for Medical Oncology

    Related medicine news :

    1. Wayne State researchers say adolescent smoking prevention programs still critical
    2. Germany launches a €16 million epigenome program
    3. Cleveland Clinic Florida receives approval for transplant programs at Weston Facilities
    4. Adolescents in substance abuse programs report using others med marijuana
    5. Implementing a therapeutic hypothermia program for post-cardiac arrest in acute care hospitals
    6. New FDA program adds to tools to curb opiod abuse in United States
    7. Surgical patient safety program lowers SSIs by one-third following colorectal operations
    8. ASH launches multi-million-dollar grant program to support critical blood disease research
    9. A nursing program shows promise for reducing deaths from chronic illnesses
    10. Scientists find new way to induce programmed cell death, or apoptosis
    11. Gallo Research Center to lead $15 million US Army-funded national research program
    Post Your Comments:
    (Date:10/13/2017)... ... 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, ... and least understood books in the Holy Scriptures, Revelation. The Book of Revelation paints ... for centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins says ...
    (Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: ... “America On The Brink” is the creation of published author, William Nowers. ... As a WWII veteran, he spent thirty years in the Navy. Following ...
    (Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... products to meet the demand of today’s consumer and regulatory authorities worldwide. From ... probiotic experts and tested to meet the highest standard. , These products ...
    (Date:10/12/2017)... ... 12, 2017 , ... Information about the technology: , Otomagnetics ... enable prevention of a major side effect of chemotherapy in children. Cisplatin and ... For cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. ...
    (Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, the Health ... Miles by Moonlight to raise money for the American Heart Association Heart Walk. Teams ... Teams will work together to keep their treadmills moving for 5 hours. Treadmills will ...
    Breaking Medicine News(10 mins):
    (Date:10/11/2017)... CHICAGO , Oct. 11, 2017  Hill-Rom Holdings, ... its Aspen Surgical facility in Las Piedras, ... surgical scalpels and blades. ... confirmed that the facility sustained minor structural damage, temporary ... Hurricane Maria. Repairs have been completed, manufacturing operations have ...
    (Date:10/4/2017)... Oct. 4, 2017  South Korean-based healthcare product Development ... aide "cprCUBE" on Kickstarter. The device will educate the ... arrests with better efficiency compared to the dated and ... feedback on efficacy of the compression for a more ... a goal to raise $5,000. ...
    (Date:10/2/2017)... , Oct. 2, 2017  AllianceRx Walgreens Prime, ... formed by Walgreens and pharmacy benefit manager Prime Therapeutics ... new brand, which included the unveiling of new signage ... , as well as at a few other company-owned ... new brand to patients, some of whom will begin ...
    Breaking Medicine Technology: